Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
PTC fails phase 3, and looks to a regulatory filing
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
Sanofi seeks to build on COPD win
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
Viking’s Voyage is not over yet
A hit on one goal helps, but future Nash data will be more decisive.
